---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-031291"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:24:45.429230+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vistagen reports Q2 net loss $6.6M; fasedienol PALISADE-2 positive; cash $37.6M + $93.5M offering

## Summary
- Net loss $6.6M for Q2 end Sep 30, 2023 vs $17.5M YoY; R&D expense decreased to $3.9M.
- Cash $37.6M at Sep 30; raised $93.5M net from public offering plus $1.5M from Fuji Pharma.
- Fasedienol PALISADE-2 Phase 3 met primary and secondary endpoints; PALISADE-3 and -4 planned 2024; NDA target 1H 2026.
- Itruvone Phase 2B for MDD and PH80 Phase 2B for hot flashes expected 2H 2024; PH80 positive Phase 2A in PMDD.

## SEC filing metadata
- accession: 0001437749-23-031291
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000143774923031291/0001437749-23-031291-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000143774923031291/vtgn20231109_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-031291
- JSON: https://secwatch.observer/filing/0001437749-23-031291.json
- Plain text: https://secwatch.observer/filing/0001437749-23-031291.txt

## Key facts
- Earnings Releases
  Vistagen Therapeutics, Inc. reported financial results for fiscal year 2024 second quarter ended September 30, 2023.
  - Period: fiscal year 2024 second quarter ended September 30, 2023
  - Result: reported results
  source text: On November 9, 2023, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release to announce the Company’s financial results for its fiscal year 2024 second quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411685/000143774923031291/0001437749-23-031291-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.